Genmab A/S (GMAB) on Decifer

Decifer ranks GMAB number 178 of 268 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 17% a year, faster than 62 in 100 companies we measure.
• It keeps about 31 cents of every sales dollar as cash, safer than 94 in 100 companies we measure.
• It earns about 9% a year on the money put into the business, better than 52 in 100 companies we measure.

The current read

The evidence on GMAB lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full GMAB research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.